Shi An, Wenwei Ouyang, Shuangshuang Wang, Juan Yuan,Xuemei Zhen*. Marital transitions and frailty among middle-aged and older adults in China: The roles of social support. SSM Population Health. 2023, 24:101497.
Xuemei Zhen, Jing Ming, Runqi Zhang, Shuo Zhang, Jing Xie, Baoguo Liu, Zijing Wang, Xiaojie Sun*. Economic burden of adult patients with β-thalassaemia major in mainland China. Orphanet Journal of Rare Diseases. 2023, 18:252.
Runqi Zhang, Shuo Zhang, Jing Ming, Jing Xie, Baoguo Liu, Cuiqian Chen, Xiaojie Sun*,Xuemei Zhen*. Predictors of health state utility values using SF-6D for Chinese adult patients with β-thalassemia major. Frontiers in Public Health. 2023, 10:1072866.
Xuemei Zhen, Cecilia Stålsby Lundborg, Xueshan Sun, Nina Zhu, Shuyan Gu, Hengjin Dong. Economic burden of antibiotic resistance in China: a national level estimate for inpatients. Antimicrobial Resistance and Infection Control. 2021, 10:5.
Shasha Guo, Qiang Sun, Xinyang Zhao, Liyan Shen,Xuemei Zhen*.Prevalence and risk factors for antibiotic utilization in Chinese children. BMC Pediatrics. 2021, 21:255.
Xuemei Zhen, Jingchunyu Chen, Xueshan Sun, Qiang Sun, Shasha Guo, Cecilia Stålsby Lundborg. Socioeconomic factors contributing to antibiotic resistance in China: a panel data analysis. Antibiotics. 2021, 10:944.
Xuemei Zhen, Cecilia Stålsby Lundborg, Xueshan Sun, Shuyan Gu, Hengjin Dong. Clinical and economic burden of carbapenem-resistant infection or colonization caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: a multicenter study in China. Antibiotics. 2020, 9:514.
Xuemei Zhen, Cecilia Stålsby Lundborg, Xueshan Sun, Shuyan Gu, Hengjin Dong. Clinical and economic burden of carbapenem-resistant infection or colonization caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: a multicenter study in China. Antibiotics. 2020, 9:514.
Xuemei Zhen, Cecilia Stålsby Lundborg, Meiling Zhang, Xueshan Sun, Yuanyuan Li, Xiaoqian Hu, Shuyan Gu, Yuxuan Gu, Jingming Wei, Hengjin Dong. Clinical and economic impact methicillin-resistant Staphylococcus aureus: a multicentre study in China. Scientific Reports. 2020, 10:3900.
Xuemei Zhen, Cecilia Stålsby Lundborg, Meiling Zhang, Xueshan Sun, Yuanyuan Li, Xiaoqian Hu, Shuyan Gu, Yuxuan Gu, Jingming Wei, Hengjin Dong. Clinical and economic impact methicillin-resistant Staphylococcus aureus: a multicentre study in China. Scientific Reports. 2020, 10:3900.
Xuemei Zhen, Cecilia Stålsby Lundborg, Meiling Zhang, Xueshan Sun, Yuanyuan Li, Xiaoqian Hu, Shuyan Gu, Yuxuan Gu, Jingming Wei, Hengjin Dong. Clinical and economic impact methicillin-resistant Staphylococcus aureus: a multicentre study in China. Scientific Reports. 2020, 10:3900.
Xuemei Zhen, Cecilia Stålsby Lundborg, Meiling Zhang, Xueshan Sun, Yuanyuan Li, Xiaoqian Hu, Shuyan Gu, Yuxuan Gu, Jingming Wei, Hengjin Dong. Clinical and economic impact methicillin-resistant Staphylococcus aureus: a multicentre study in China. Scientific Reports. 2020, 10:3900.
Xuemei Zhen, Yuanyuan Li, Yixi Chen, Peng Dong, Stephanie Liu, Hengjin Dong. Effect of multiple drug resistance on total medical costs among patients with intra-abdominal infections in China. PloS One. 2018, 13:e0193977.
Xuemei Zhen, Xueshan Sun, Hengjin Dong. Health technology assessment and its use in drug policies in China. Value in Health Regional Issues. 2018, 15:138-48.
Xuemei Zhen, Xueshan Sun, Hengjin Dong. Health technology assessment and its use in drug policies in China. Value in Health Regional Issues. 2018, 15:138-48.
JiaminWang,Xuemei Zhen, Peter C Coyte, Di Shao, Ni Zhao, Lele Chang, Yujia Feng, Xiaojie Sun. Association between online health information-seeking behavior by caregivers and delays in pediatric cancer: mixed methods study in China. Journal of Medical Internet Research. 2023, 25:e46953.
Xueshan Sun,Xuemei Zhen, Xiaoqian Hu, Yuanyuan Li, Shuyan Gu, Yuxuan Gu, Zixuan Zhao, Wei Yang, Hengjin Dong. Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis. Cost Effectiveness and Resource Allocation. 2021, 19:22.
Xueshan Sun,Xuemei Zhen, Xiaoqian Hu, Yuanyuan Li, Shuyan Gu, Yuxuan Gu, Zixuan Zhao, Wei Yang, Hengjin Dong. Cost-utility analysis of imrecoxib compred with celecoxib for patients with osteoarthritis. Annals of Translational Medicine. 2021, 9:575-575.
